Serological evidence of respiratory syncytial virus infection in sheep

Berthiaume, Laurent; Joncas, Jean H.; Boulay, Gaston; Pavilanis, V.

doi:10.1136/vr.93.12.337-a

Cited by 19 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The respiratory system of lambs and human infants share many anatomical, physiological and developmental features that increase the translational value of studies performed in lambs for inhaled drugs 15 20 Colostrum-deprived (lacking maternal antibody and thus any anti-RSV antibodies) neonatal lambs are highly relevant for the study of RSV infection due to their natural susceptibility to ovine, bovine and human strains of RSV 30-32 and to the similarities in disease pathogenesis to that of human infants 17 33 This lamb hRSV-infection model therefore constitutes a valuable tool for use in pre-clinical studies of vaccines or therapeutics.…”

Section: Discussionmentioning

confidence: 99%

Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

Mora

Detalle

Gallup

et al. 2018

mAbs

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory disease in infants and young children worldwide. Currently, treatment is supportive and no vaccines are available. The use of newborn lambs to model hRSV infection in human infants may provide a valuable tool to assess safety and efficacy of new antiviral drugs and vaccines. ALX-0171 is a trivalent Nanobody targeting the hRSV fusion (F) protein and its therapeutic potential was evaluated in newborn lambs infected with a human strain of RSV followed by daily ALX-0171 nebulization for 3 or 5 consecutive days.Colostrum-deprived newborn lambs were infected with hRSV-M37 before being treated by daily nebulization with either ALX-0171 or placebo. Two different treatment regimens were examined: day 1–5 or day 3–5 post-infection. Lambs were monitored daily for general well-being and clinical parameters. Respiratory tissues and bronchoalveolar lavage fluid were collected at day 6 post-inoculation for the quantification of viral lesions, lung viral titers, viral antigen and lung histopathology.Administration by inhalation of ALX-0171 was well-tolerated in these hRSV-infected newborn lambs. Robust antiviral effects and positive effects on hRSV-induced lung lesions and reduction in symptoms of illness were noted. These effects were still apparent when treatment start was delayed and coincided with peak viral loads (day 3 post-infection) and at a time point when signs of RSV disease were apparent. The latter design is expected to have high translational value for planned clinical trials. These results are indicative of the therapeutic potential of ALX-0171 in infants.

show abstract

Section: Discussionmentioning

confidence: 99%

Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

Mora

Detalle

Gallup

et al. 2018

mAbs

View full text Add to dashboard Cite

show abstract

“…Respiratory syncytiM virus has also been isolated from a naturally infected pygmy goat with respiratory disease (160) and antibodies found in 5 of 10 goat sera (230) but little is known about the natm~M incidence of RSV in this species. Reports that antibodies to RSV are widespread in sheep (19) and cats (216,230) have not been confirmed by isolation of virus from naturally infected animals. However, bovine RSV will infect lambs experi-mentMly (159).…”

Section: Historymentioning

confidence: 99%

Respiratory syncytial virus

Stott¹,

Taylor²

1985

Archives of Virology

211

125

View full text Add to dashboard Cite

“…Bovine and human RSV strains are currently considered to be antigenically related (BRUGERE-PICOUX et al, 1985). Although greater susceptibility has been reported in cattle, RSV may also affect other domestic species (BERTHIAUME et al, 1973;BRYSON et al, 1988a). Complement-fixing antibodies against RSV (BERTHIAUME et al, 1973), and neutralizing antibodies to bovine respiratory syncytial virus (BRSV;SMITH et al, 1975) have been reported in sheep serum.…”

Section: Introductionmentioning

confidence: 99%

Pathological Study of Experimentally Induced Bovine Respiratory Syncytial Viral Infection in Lambs

Masot¹,

Gómez-Tejedor²,

Gómez³

et al. 1996

Journal of Veterinary Medicine, Series B

View full text Add to dashboard Cite

Summary An experimental model was designed to characterize lesions in the lung of lambs inoculated with bovine respiratory syncytial virus (BRSV). Twenty‐five Merino lambs of both sexes, with a live weight of 17 ± 3 kg, received an intratracheal inoculation of 20 ml saline solution containing 1.26 times 106 TCID50 BRSV (strain NMK‐7) per ml. Lambs were slaughtered 1, 3, 7, 11 and 15 days postinoculation (DPI), and samples were taken for analysis using light‐microscopic and immunohistochemical techniques. The results reflected the effect of the virus on airway epithelia. The presence of BRSV in ciliated bronchial and bronchiolar epithelial cells gave rise to cytopathological changes, including loss of cilia and cell necrosis; these changes might be expected to decrease the efficiency of mucociliary clearance, favouring the development of secondary bacterial bronchopneumonia. These results suggest a reduction in BRSV tropism for alveolar epithelia compared to bronchial and bronchiolar epithelia. Light‐microscopic analysis revealed a narrowing of alveolar and airway lumina and a considerable interstitial inflammatory reaction.

show abstract

Serological evidence of respiratory syncytial virus infection in sheep

Cited by 19 publications

References 0 publications

Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

Respiratory syncytial virus

Pathological Study of Experimentally Induced Bovine Respiratory Syncytial Viral Infection in Lambs

Contact Info

Product

Resources

About